Evidence map›Paper›PMID 41194139›Full record

ArticleBMC complementary medicine and therapies2025

Correction: Inhibitory effect of [6]-shogaol against 3CLpro activity and SARS-CoV-2 infection.

Takashi Tanikawa, Tsuyoshi Hayashi, Yuka Kiba, Hitoshi Kamauchi, Yuichi Someya, Masashi Kitamura

Abstract readPublished Erratum
In one paragraph

Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Takashi TanikawaFaculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1, Keyakidai, 350-0295, Sakado, Saitama, Japan. tanikawa@josai.ac.jp.
Tsuyoshi HayashiDepartment of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Yuka KibaFaculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1, Keyakidai, 350-0295, Sakado, Saitama, Japan.
Hitoshi KamauchiFaculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1, Keyakidai, 350-0295, Sakado, Saitama, Japan.
Yuichi SomeyaDepartment of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Masashi KitamuraFaculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1, Keyakidai, 350-0295, Sakado, Saitama, Japan. kitamura@josai.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41194139
PMCPMC12590810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.